Reprieve Cardiovascular — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Reprieve Cardiovascular is a private, pre-revenue medical device innovator targeting the costly and prevalent problem of fluid congestion in heart failure. Its core technology, the Reprieve System, is a personalized intelligent decongestion management platform that provides physicians with real-time feedback and control during diuretic therapy, aiming to optimize fluid removal while mitigating kidney injury risks. The company is currently conducting the FASTR Pilot clinical trial to evaluate its system against standard care and is led by an experienced team with strong venture backing from firms like Arboretum Ventures.

Cardiovascular

Technology Platform

The Reprieve System is an intelligent decongestion management (IDM) platform that combines real-time patient monitoring with controlled diuretic delivery to personalize and optimize fluid removal for heart failure patients.

Opportunities

The massive and growing global heart failure patient population, coupled with the high cost of hospitalizations primarily driven by fluid congestion, presents a significant addressable market.

There is a clear unmet need for smarter, safer tools to manage diuretic therapy, offering a strong value proposition to hospitals seeking to reduce length of stay and complications.

Risk Factors

The company's fate depends entirely on the success of its ongoing FASTR clinical trial.

Regulatory hurdles, future challenges in achieving market adoption and reimbursement, and competition from both novel pharmaceuticals and other device-based decongestion strategies pose significant risks.

Competitive Landscape

Competition includes generic intravenous diuretics (the entrenched standard of care), novel diuretic drugs in development, alternative fluid removal devices like aquapheresis systems (e.g., CHAP from Nuwellis), and a growing ecosystem of digital health and monitoring solutions for heart failure management. Reprieve's differentiation lies in its focus on intelligently controlling the delivery of the standard therapy rather than replacing it.

More companies in Digital Health & Biotech SaaS →More companies in United States →